BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10813207)

  • 1. Progressive systemic sclerosis and the lung.
    Veeraraghavan S; Sharma OP
    Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scleroderma lung disease.
    Solomon JJ; Olson AL; Fischer A; Bull T; Brown KK; Raghu G
    Eur Respir Rev; 2013 Mar; 22(127):6-19. PubMed ID: 23457159
    [No Abstract]   [Full Text] [Related]  

  • 3. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
    Jain S; Shahane A; Derk CT
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging lung disease in systemic sclerosis.
    Strollo D; Goldin J
    Curr Rheumatol Rep; 2010 Apr; 12(2):156-61. PubMed ID: 20425026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
    Mangat P; Conron M; Gabbay E; Proudman SM;
    Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Systemic sclerosis].
    Schinke S; Riemekasten G
    Internist (Berl); 2019 Dec; 60(12):1251-1269. PubMed ID: 31754753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
    Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
    Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategies in the management of systemic sclerosis.
    Allanore Y; Avouac J; Wipff J; Kahan A
    Expert Opin Pharmacother; 2007 Apr; 8(5):607-15. PubMed ID: 17376016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lung in systemic sclerosis.
    Steen VD
    J Clin Rheumatol; 2005 Feb; 11(1):40-6. PubMed ID: 16357695
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
    Morelli S; Ferri C
    J Rheumatol; 1996 Apr; 23(4):789-91. PubMed ID: 8730152
    [No Abstract]   [Full Text] [Related]  

  • 11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs and therapeutics for systemic sclerosis.
    Lee JJ; Pope JE
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
    Wells AU; Steen V; Valentini G
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic sclerosis sine scleroderma presenting as pulmonary intersticial fibrosis.
    Vañó Sanchis D; Arranz Garcia G; Yglesias PJ
    Clin Rheumatol; 2006 May; 25(3):382-3. PubMed ID: 16211337
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.
    Ohar J; Polatty C; Robichaud A; Fowler A; Vetrovec G; Glauser F
    Chest; 1985 Oct; 88(4 Suppl):263S-265S. PubMed ID: 4042734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors relating to impaired stroke volume during the 6-minute walk test in patients with systemic sclerosis.
    Someya F; Mugii N; Oohata S
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):152-156. PubMed ID: 27463117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K; Pope JE
    Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment and management of scleroderma lung disease.
    Bolster MB; Silver RM
    Curr Opin Rheumatol; 1999 Nov; 11(6):508-13. PubMed ID: 10551676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
    Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
    J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.